The number of new or newly enlarged hyperintense lesions on T@-weighted magnetic resonance imaging ( MRI ) over a period of @ weeks was lower with daclizumab HYP than with interferon beta-@a ( @ vs. @ ; @ % lower number of lesions with daclizumab HYP ; P < @ ) .